Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

Dyne Therapeutics (Nasdaq: DYN) will announce topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, DYNE-251) on December 8, 2025.

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) will announce topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, DYNE-251) on December 8, 2025.

The company will host an investor conference call and webcast at 8:00 a.m. ET on that day; a press release will be issued before the event. The webcast and an accompanying slide presentation will be available on Dyne’s Events & Presentations page, and a replay will be accessible for 90 days after the presentation.

Argus Session date unavailable

+9.47% session move Open Argus

Details

News Market Reaction – DYN

The recorded move for DYN in the trading session of this news was +9.47%.

Data tracked by StockTitan Argus. Session date unavailable.

Key Figures

Topline data date: December 8, 2025 Call time: 8:00 a.m. ET Webcast replay period: 90 days

Topline data date

December 8, 2025

DELIVER REC topline results release date

Call time

8:00 a.m. ET

Investor conference call and webcast start time

Webcast replay period

90 days

Replay availability after the investor presentation

Historical Context

5 past events · Latest: Nov 05

5 events

1. Nov 05

   Earnings and pipeline

   24h Move

   -2.9%

   Q3 2025 results, cash runway and timelines for DYNE-251 and DYNE-101.

2. Nov 03

   Investor conferences

   24h Move

   +6.8%

   Announcements of multiple healthcare conference presentations and webcasts.

3. Oct 06

   Clinical data update

   24h Move

   -3.1%

   One-year ACHIEVE Phase 1/2 data for DYNE-101 showing functional gains.

4. Oct 02

   Board appointment

   24h Move

   +4.1%

   Appointment of experienced executive Brian Posner to the board.

5. Sep 29

   Regulatory designation

   24h Move

   -5.9%

   Japanese Orphan Drug designation for DYNE-251 and recap of DELIVER data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registrational expansion cohort, phase 1/2, clinical trial, webcast

4 terms

registrational expansion cohort medical

"topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial"

A registrational expansion cohort is a larger, focused group added to a clinical trial to gather the specific safety and effectiveness data regulators need to decide on drug approval. Think of it as a final test drive with more drivers and clearer goals so regulators can judge whether the treatment works for a defined patient group. For investors, its start, progress, or outcome can materially change a drug’s approval odds and a company’s value.

phase 1/2 medical

"from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

clinical trial medical

"DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

webcast technical

"to host a webcast at 8:00 a.m. ET"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.

Investor Conference Call and Webcast
The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne’s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ and follow us on X, LinkedIn and Facebook.

Contacts:

Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Dyne Therapeutics (DYN) announce topline REC results from the DELIVER trial?

Dyne will announce topline REC results on December 8, 2025.

What time is the Dyne Therapeutics (DYN) investor webcast for DELIVER REC results?

The investor webcast and conference call are scheduled for 8:00 a.m. ET on December 8, 2025.

Where can investors watch the Dyne (DYN) DELIVER REC results webcast and access slides?

The webcast and slide presentation will be on Dyne’s Events & Presentations page at https://investors.dyne-tx.com/news-and-events/events-and-presentations.

Will Dyne (DYN) provide a press release before the DELIVER webcast?

Yes, the company intends to issue a press release prior to the start of the webcast.

How long will the replay of Dyne’s (DYN) DELIVER presentation be available?

A replay will be accessible for 90 days following the presentation.

What drug and trial does Dyne (DYN) plan to report REC topline results for on December 8, 2025?

Dyne plans to report REC topline results for zeleciment rostudirsen (z-rostudirsen, DYNE-251) from the Phase 1/2 DELIVER trial.